Lantheus (LNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $110.00 price target.
Tara Bancroft has given her Buy rating due to a combination of factors including Lantheus’s strong revenue performance and future growth prospects. The company’s 2024 revenue of $1.53 billion was consistent with guidance and showed an 18.3% year-over-year increase, driven by the successful performance of Pylarify, which became the first blockbuster radiodiagnostic with a 24.3% increase in sales.
Bancroft also notes that the 2025 guidance reflects expectations for continued growth, with anticipated revenue ranging from $1.55 billion to $1.61 billion. This growth is expected to be supported by low to mid-single digit percentage increases in both Pylarify and Definity product sales. The strategic partnerships and pricing adjustments are expected to stabilize, further enhancing the company’s financial outlook and justifying the Buy rating.
Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Lantheus, and Merus. According to TipRanks, Bancroft has an average return of -8.7% and a 22.83% success rate on recommended stocks.
In another report released on February 19, Leerink Partners also maintained a Buy rating on the stock with a $125.00 price target.